How Biotech Investors Can Turn FDA Obstacles Into Profitable Opportunities

The Life Sciences Report | |

Being temporarily burned by the U.S. Food and Drug Administration can be a mixed blessing for a biotech with a good product in the pipeline. In an interview with The Life Sciences Report, Chen

3 Rules Biotech Investors Need to Live By

The Life Sciences Report | |

Excellent diligence doesn't always mean you'll be saved from a nasty surprise. The nature of investing in biotech means assuming the risk that a therapeutic development program may fail.

Sponsored Financial Content

Market Movers